PRQR
Income statement / Annual
Last year (2024), ProQR Therapeutics N.V.'s total revenue was $18.91 M,
an increase of 190.22% from the previous year.
In 2024, ProQR Therapeutics N.V.'s net income was -$27.76 M.
See ProQR Therapeutics N.V.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$18.91 M |
$6.51 M |
$4.04 M |
$1.35 M |
$0.00 |
$1.93 M |
$4.94 M |
-$1.53 M |
$2.28 M |
$9.41 M |
| Cost of Revenue |
$0.00
|
$133,524.00
|
$2.48 M
|
$0.00
|
$2.19 M
|
$116.82 M
|
$983,511.00
|
$1.00 M
|
$1.28 M
|
$482,849.00
|
| Gross Profit |
$18.91 M
|
$6.38 M
|
$1.56 M
|
$1.35 M
|
-$2.19 M
|
-$114.89 M
|
$3.96 M
|
-$2.53 M
|
$1.00 M
|
$8.92 M
|
| Gross Profit Ratio |
1
|
0.98
|
0.39
|
1
|
0
|
-59.44
|
0.8
|
1.65
|
0.44
|
0.95
|
| Research and Development Expenses |
$36.36 M
|
$25.15 M
|
$50.87 M
|
$42.22 M
|
$38.14 M
|
$46.49 M
|
$29.51 M
|
$31.15 M
|
$31.92 M
|
$23.40 M
|
| General & Administrative Expenses |
$13.66 M
|
$16.24 M
|
$18.65 M
|
$17.37 M
|
$13.69 M
|
$12.89 M
|
$12.54 M
|
$10.84 M
|
$9.48 M
|
$6.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.66 M
|
$16.24 M
|
$18.65 M
|
$17.37 M
|
$13.69 M
|
$12.89 M
|
$12.54 M
|
$10.84 M
|
$9.48 M
|
$6.84 M
|
| Other Expenses |
-$640,000.00
|
-$3.01 M
|
-$765,000.00
|
-$1.04 M
|
$9.37 M
|
$1.93 M
|
$5.76 M
|
$1.50 M
|
$1.83 M
|
$3.24 M
|
| Operating Expenses |
$49.38 M
|
$38.37 M
|
$68.75 M
|
$58.55 M
|
$51.82 M
|
$59.38 M
|
$42.05 M
|
$41.99 M
|
$41.40 M
|
$30.24 M
|
| Cost And Expenses |
$49.38 M
|
$38.37 M
|
$68.75 M
|
$58.55 M
|
$51.82 M
|
$59.38 M
|
$42.05 M
|
$41.99 M
|
$41.40 M
|
$30.24 M
|
| Interest Income |
$3.25 M
|
$2.59 M
|
$106,000.00
|
$5,000.00
|
$313,000.00
|
$402,000.00
|
-$792,000.00
|
-$3.18 M
|
$470,000.00
|
$6.17 M
|
| Interest Expense |
$1.08 M
|
$1.20 M
|
$5.13 M
|
$3.41 M
|
$2.04 M
|
$1.08 M
|
$810,000.00
|
$596,000.00
|
$538,000.00
|
$395,000.00
|
| Depreciation & Amortization |
$2.76 M
|
$2.51 M
|
$2.48 M
|
$2.42 M
|
$2.19 M
|
$2.05 M
|
$983,511.00
|
$1.00 M
|
$1.28 M
|
$480,000.00
|
| EBITDA |
-$24.12 M |
-$24.10 M |
-$56.46 M |
-$54.95 M |
-$136.56 M |
-$174.27 M |
-$35.29 M |
$0.00 |
-$120.55 M |
-$84.24 M |
| EBITDA Ratio |
-1.28
|
-3.7
|
-13.99
|
-40.58
|
0
|
-90.15
|
-7.14
|
0
|
-52.83
|
-8.96
|
| Operating Income Ratio |
-1.61
|
-4.89
|
-16.03
|
-42.24
|
0
|
-29.72
|
-7.35
|
26.49
|
-17.34
|
-2.87
|
| Total Other Income/Expenses Net |
$2.51 M
|
$4.05 M
|
$1.05 M
|
-$3.47 M
|
-$4.12 M
|
$117.65 M
|
-$792,000.00
|
$850,314.00
|
$470,000.00
|
$6.17 M
|
| Income Before Tax |
-$27.96 M
|
-$27.81 M
|
-$64.80 M
|
-$61.56 M
|
-$46.49 M
|
-$56.61 M
|
-$37.09 M
|
-$43.67 M
|
-$39.10 M
|
-$20.83 M
|
| Income Before Tax Ratio |
-1.48
|
-4.27
|
-16.05
|
-45.47
|
0
|
-29.29
|
-7.51
|
28.56
|
-17.14
|
-2.21
|
| Income Tax Expense |
-$197,000.00
|
-$78,000.00
|
$96,000.00
|
$117,000.00
|
$124,000.00
|
$132,000.00
|
$1,000.00
|
$2,000.00
|
-$470,000.00
|
-$6.17 M
|
| Net Income |
-$27.76 M
|
-$28.12 M
|
-$64.89 M
|
-$61.68 M
|
-$46.61 M
|
-$56.75 M
|
-$36.89 M
|
-$43.64 M
|
-$39.10 M
|
-$20.83 M
|
| Net Income Ratio |
-1.47
|
-4.32
|
-16.07
|
-45.55
|
0
|
-29.36
|
-7.47
|
28.54
|
-17.14
|
-2.21
|
| EPS |
-0.34 |
-0.35 |
-0.91 |
-0.96 |
-0.93 |
-1.38 |
-1.08 |
-1.72 |
-1.67 |
-0.89 |
| EPS Diluted |
-0.34 |
-0.35 |
-0.91 |
-0.96 |
-0.93 |
-1.38 |
-1.08 |
-1.72 |
-1.67 |
-0.89 |
| Weighted Average Shares Out |
$81.67 M
|
$81.01 M
|
$71.64 M
|
$64.18 M
|
$50.06 M
|
$41.04 M
|
$34.05 M
|
$25.37 M
|
$23.35 M
|
$23.34 M
|
| Weighted Average Shares Out Diluted |
$81.67 M
|
$81.01 M
|
$71.64 M
|
$64.18 M
|
$50.06 M
|
$41.04 M
|
$34.05 M
|
$25.37 M
|
$23.35 M
|
$23.34 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
